Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis

By Revicki Dennis A.   Jin Ying   Wilson Hilary D.   Chau Dina   Viswanathan Hema N.  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 8-14

Informa Healthcare

Access to resources Recommend Favorite

Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis

By Au Shiu-Chung  

Journal of Dermatological Treatment, Vol. 24, Iss. 3, 2013-06 ,pp. : 179-187

Informa Healthcare

Access to resources Recommend Favorite

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

By Revicki Dennis   Willian Mary Kaye   Menter Alan   Gordon Kenneth   Kimball Alexa   Leonardi Craig   Langley Richard   Kimel Miriam   Okun Martin  

Journal of Dermatological Treatment, Vol. 18, Iss. 6, 2007-01 ,pp. : 341-350

Informa Healthcare

Access to resources Recommend Favorite

An update on drug–drug interactions with biologics for the treatment of moderate-to-severe psoriasis

By Gupta Rishu   Levin Ethan   Wu Jashin J.   Koo John   Liao Wilson  

Journal of Dermatological Treatment, Vol. 25, Iss. 1, 2014-02 ,pp. : 87-89

Informa Healthcare

Access to resources Recommend Favorite